Lyon

• A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen i … Recruiting
  2024-514899-41-00 4 2024-10-31 Breast cancer
• Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects … Recruiting
  2023-505334-10-01 7 2024-10-30 Unresectable, Locally Advanced, or Metastatic Solid Tumors
• Beamion PANTUMOR-1: A study to test whether zongertinib helps people with advanced cancers with HER2 alterations Recruiting
  2023-510429-14-00 4 2024-10-22 HER2-mutated or overexpressed/amplified solid tumours
• FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting
  2024-515300-39-00 4 2024-10-18 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 Primary Myelofibrosis
• An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch … Recruiting
  2024-516782-36-00 4 2024-10-15 metastatic or recurrent endometrial or ovarian carcinosarcoma
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-507482-26-00 5 2024-10-04 Castrate-resistant prostate cancer with oligometastases on functional
• ARGO Colchicine versus Placebo in Acute Myocarditis Patients to Reduce Late Gadolinium Enhancement Mass on Cardiac Magnetic Resonance and th … Recruiting
  2024-514610-13-00 5 2024-10-04 patients suffering from acute myocarditis confirmed on Cardiac magneti
• Linezolid or vancomycin surgical site infection prophylaxis LOVip Recruiting
  2023-504986-22-00 5 2024-09-30 surgical antibiotic prophylaxis
• tislelizUMaB in canceR patients with molEcuLar residuaL disease (UMBRELLA) Recruiting
  2023-503316-33-00 5 2024-09-26 patients with a positive status for molecular residual disease (MRD) [
• A clinical trial to learn about the safety and effects of STX-241, a new oral anticancer drug for the treatment of patients with advanced lu … Recruiting
  2023-510203-21-00 7 2024-09-24 locally advanced or metastatic non-small cell lung cancer (NSCLC) resi
• PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge … Recruiting
  2024-511070-68-01 5 2024-09-24 Ampullary adenocarcinoma
• A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumors Recruiting
  2024-511238-11-00 1 2024-09-20 Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lu
• FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage Recruiting
  2024-515118-42-00 11 2024-09-10 Colorectal cancer
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients with Advanced or Metastatic Prostate Cancer Recruiting
  2023-504013-68-00 1 2024-09-06 Advanced or Metastatic Prostate Cancer
• Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard … Recruiting
  2022-502408-57-00 5 2024-09-04 Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
• An Open-Label, Multicenter, Multi-Arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults with Advanced Solid Tum … Recruiting
  2022-502757-34-00 1 2024-08-20 Advanced solid tumors
• PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting
  2024-515297-27-00 5 2024-08-14 colon carcinoma
• First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer Recruiting
  2023-508435-31-00 1 2024-08-09 Advanced Solid Tumors, Advanced Breast Cancer
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro … Recruiting
  2023-508005-24-00 5 2024-08-01 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• HydroxyChloroquine as steroid-sparing Agent in Extra-pulmonary SARcoidosis. A multicenter, prospective, placebo-controlled, randomized trial … Recruiting
  2022-502155-65-00 5 2024-07-30 Extra pulmonary sarcoidosis
• SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa … Recruiting
  2023-508260-30-01 5 2024-07-30 Patients with poor prognostic OVARian cancers based on the tumor prima
• Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu … Recruiting
  2024-515788-73-00 4 2024-07-30 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IM
• Ezabenlimab (BI 754091) and DCFm (docetaxel, cisplatin and 5-fluorouracil) followed by chemoradiotherapy for the treatment of stage III anal … Recruiting
  2024-514083-31-00 4 2024-07-26 squamous cell anal carcinoma

Showing 289–312 of 875 trials